Trastuzumab deruxtecan: Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.
Study summary
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Aged ≥18 and older
* Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
* ECOG 0-1
Exclusion Criteria:
* During pregnancy and lactation
Primary outcome measure(s)
Progression-Free Survival (PFS) — From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years) The time from the date of starting trastuzumab deruxtecan to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.
Trial sites (1)
Facility
City
Region
Status
Renji Hospital, School of Medicine, Shanghai Jiaotong University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.